Uncover key drivers, emerging technologies, and competitive movements shaping the adalimumab, infliximab and etanercept biosimilars market from 2026–2035 with trusted insights from The Business Research Company
What are the forecasted starting (2026) and ending (2030) market sizes for the Adalimumab, Infliximab and Etanercept Biosimilars Market?
The market for adalimumab, infliximab, and etanercept biosimilars has experienced significant expansion recently. This market is projected to expand from $4.96 billion in 2025 to $5.47 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.3%. Historically, this growth has been driven by factors such as the increasing incidence of autoimmune diseases, the substantial cost of originator biologics, greater recognition of biosimilars, advancements in biologics manufacturing, and favorable government policies.
The adalimumab, infliximab and etanercept biosimilars market is anticipated to experience substantial growth in the upcoming years. It is projected to expand to $8.05 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.1%. This expansion over the forecast period is attributable to breakthroughs in precision medicine, the enlargement of biosimilar pipelines, increasing healthcare spending, the broader embrace of digital health technologies, and a growing older demographic. Significant trends for the forecast period include the increasing uptake and market presence of biosimilars, the development of economical TNF-alpha inhibitors, favorable regulatory approvals and policy backing, the enlargement of hospital and retail pharmacy infrastructures, and the implementation of customized treatment plans.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp
What Drivers Are Supporting Technological Adoption In The Adalimumab, Infliximab and Etanercept Biosimilars Market?
The increasing occurrence of autoimmune diseases is anticipated to propel the expansion of the adalimumab, infliximab, and etanercept biosimilars market in the coming years. Autoimmune disease refers to conditions or disorders that arise from immune system dysfunction, where immune cells attack the body’s healthy cells. Adalimumab, infliximab, and etanercept are biological drugs, specifically tumor necrosis factor (TNF) alpha inhibitors, utilized for treating various autoimmune diseases. For instance, in 2023, Johns Hopkins University, a US-based private research university, reported that approximately 10 million people in the US, which accounts for 3% of the population, suffer from all autoimmune illnesses. Consequently, the rising prevalence of autoimmune diseases is a key driver for the growth of the adalimumab, infliximab, and etanercept biosimilars market.
Which Segments Are Contributing To The Growth Of The Adalimumab, Infliximab and Etanercept Biosimilars Market?
The adalimumab, infliximab and etanercept biosimilars market covered in this report is segmented –
1) By Product: Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications
Subsegments:
1) By Adalimumab Biosimilars: Amjevita (Amgen), Hyrimoz (Sandoz), Cyltezo (Boehringer Ingelheim), Others
2) By Infliximab Biosimilars: Inflectra (Pfizer), Remsima (Celltrion), Ixifi (Pfizer), Others
3) By Cipleumab: Cipleumab Biosimilars, Other Biosimilars in Development
Which Trends Are Influencing The Performance And Direction Of The Adalimumab, Infliximab and Etanercept Biosimilars Market?
Companies operating within the adalimumab, infliximab, and etanercept biosimilars market are concentrating on technological innovations, such as high-concentration, citrate-free biosimilars, to satisfy the growing need for more patient-friendly formulations, greater affordability, and wider market access. These advanced versions provide the identical therapeutic monoclonal antibody structure as conventional biosimilars but with a more comfortable injection experience, causing less discomfort during administration, potentially boosting patient adherence and transition rates compared to standard buffered formulations. For instance, in June 2023, Celltrion USA, a US-based biopharmaceutical company, launched Yuflyma (adalimumab-aaty), a citrate-free, high-concentration (100 mg/mL) biosimilar of Humira (adalimumab), designed to offer the same potency and efficacy in a more convenient format for patients. Yuflyma delivers the complete therapeutic effect of adalimumab, with the added advantage of improved tolerability due to reduced injection pain, fostering broader adoption in the immunology market, particularly for chronic inflammatory diseases.
Who Are The Prominent Global Companies Shaping The Adalimumab, Infliximab and Etanercept Biosimilars Market Landscape?
Major companies operating in the adalimumab, infliximab and etanercept biosimilars market are Biogen, Novartis (Sandoz), Pfizer, Amgen, Celltrion, Samsung Bioepis (Samsung Biologics), Hetero Drugs Limited, Fresenius Kabi AG, Boehringer Ingelheim, Biocon, Zydus Lifesciences Limited, Reliance Life Sciences, Torrent Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Cipla Limited, Zhejiang Hisun Pharmaceutical Co. Ltd, Bio-Thera Solutions Ltd, Innovent Biologics (Suzhou) Co. Ltd, Janssen Biologics BV, Shanghai CP Guojian Pharmaceutical Co. Ltd, Sansheng Guojian, Shanghai Junshi Biosciences Co. Ltd, Mabwell Bioscience Co. Ltd, LG Chem, Nippon Kayaku, Mochida Pharmaceutical Co. Ltd, mAbxience, Allergan, Microgen, Geropharm, Valenta, NovaMedica Veropharm, Biocad
Access The Complete Report For Deeper Market Insights:
Which Geographic Areas Are Emerging As Strong Markets For The Adalimumab, Infliximab and Etanercept Biosimilars Market?
North America was the largest region in the adalimumab, infliximab, and etanercept biosimilars market in 2025. The regions covered in the adalimumab, infliximab and etanercept biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Adalimumab, Infliximab and Etanercept Biosimilars Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=3473&type=smp
Browse Through More Reports Similar to the Global Adalimumab, Infliximab and Etanercept Biosimilars Market 2026, By The Business Research Company
Adalimumab Infliximab And Etanercept Biosimilars Market 2026
Bevacizumab Biosimilars Market Report 2026
https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report
Biosimilar Market Report 2026
https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model